AB0153 REAL LIFE SEVERE INFECTIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS ON TREATMENT WITH BIOLOGICAL THERAPY AND JAKI
Authors: L. Vega, I. Calvo, O. Ibarguengoitia, D. Montero, C. García, J. M. Blanco, M. E. Ruiz, A. R. Inchaurbe, I. Torre, C. E. Perez, O. Fernandez, E. Cuande, M. R. Exposito-Molinero, I. Gorostiza, M. L. García Vivar, E. Galindez
Journal: Annals of the Rheumatic Diseases (2021)

Background: Infections are one of the main complications among patients with rheumatoid arthritis (RA) with immunosuppressive treatment. The differences between treatments and the influence of other factors is unclear. Objectives: To evaluate the frequency and factors associated with serious infections in patients with RA treated with biological therapy (BT) and JAKi and the differences between treatments. Methods: Descriptive and retrospective study (January 2015-December 2020) of patients with RA treated with BT (TNFi, non-TNFi) and JAKi (tofacitinib, bariticinib, upadacitinib) in a single center. Severe infection was considered a life-threatening infection or one that required hospitalization and intravenous treatment. Epidemiological variables, clinical characteristics, Charlson comorbidity index, type of BT or JAKi and concomitant treatment were collected. For the analysis frequencies and percentages are used in qualitative variables and mean ± SD in the quantitative ones. Statistical analysis was performed with IBM SPSS v 23. Results: We registered 257 patients (84.4% women) mean aged 56.1±13.4 years. RF was positive in 86.8%, anti-CCP in 75.9% and 16.5 % presented extra-articular manifestations (nodulosis 9.7%, intersticial lung disease 4.3%, other 1.5%). At the start of the study, 157 (61.1%) patients were with TNFi, 80 (31.1%) with non-TNFi and 20 (7.8%) with JAKi. Conventional synthetic DMARDs (csDMARDs) were used in 86% of cases (methotrexate 71.1%, leflunomide 21.2%, other 7.7%). During the study, 162 (63%) patients continued with the same treatment and in 95 (37%) it was changed at least once. 3 patients discontinued the treatment. At the end of the study, 126 (49%) patients were with TNFi, 81 (31.5%) with non-TNFi and 47 (18.3%) with JAKi. Severe infection was developed in 28 (10.9%) patients (13 respiratory, 5 urinary, 5 cellulitis, 4 sepsis, 1 osteomyelitis) among them 2 patients had severe infection and herpes zoster at the same time and 3 developed a second infection. 14 (50%) patients were with TNFi, 8 (28.6%) with non-TNFi and 6 (21.4%) with JAKi. Table 1 The inflammatory activity of RA was mild at the time of infection (DAS28: 2.6±1.1). The median time until infection was: TNFi 45.25 [4.9-202.3] months, non- TNFi 19.14 [4.9-72.5] months and JAKi 17.63 [1.1-29.2] months. The Charlson index, concomitant use of glucocorticoids (GCC) at lower doses than 10mg/d, chronic obstructive pulmonary disease (COPD), diabetes (DM), moderate-severe renal insufficiency, congestive heart failure (CHF) and peripheral vascular disease were statistically significantly associated with infection. Table 1. TABLE 1. CHARACTERISTICS OF PATIENTS WITH INFECTION VS. WITHOUT INFECTION INFECTION YES n:28 NO n:229 p FEMALE , n (%) 22 (78.6) 195 (85.2) 0.406 AGE years , (mean±SD) 57.7 ± 13.9 55.9 ± 13.4 0.507 AGE ≥ 65 n (%) 10 (35.7) 68 (29.7) 0.513 RF +, n (%) 25 (89.3) 198 (86.5) 0.677 ANTI-CCP +, n (%) 21 (75) 174 (75.1) 1.00 ILD , n (%) 1 (3.5) 10 (4.3) 0.809 ALCOHOL , n (%) 3 (10.7) 17 (7.4) 0.465 SMOKER , n (%) 10 (35.7) 60 (26.2) 0.244 COPD , n (%) 7 (25) 24 (10.5) 0.026* DM , n (%) 7 (25) 19 (8.3) 0.013* CHF , n (%) 4 (14.3) 1 (0.4) 0.001* RENAL INSUFFICIENCY , n (%) 3 (10.7) 2 (0.9) 0.010* PERIPHERAL VASCULAR DISEASE , n (%) 9 (32.1) 22 (9.6) 0.002* CHARLSON INDEX (mean±SD) 1.64 ± 2.1 0.63 ± 1.2 0.001* TNFi , n (%) NON-TNFi n (%) JAKi, n (%) 14 (50) 112 (48.9) 8 (28.6) 73 (31.9) 6 (21.4) 41 (17.9) csDMARDs , n (%) 22 (78.6) 159 (69.4) 0.317 GCC dose &lt;10mg/d, n (%) 17 (60.8) 111 (48.5) 0.007* Conclusion: In our study, 10.9% of patients with RA treated with BT or JAKi developed severe infection during 5 years of follow-up. Concomitant GCC therapy and comorbidity increased the risk of presenting this complication. Disclosure of Interests: None declared